The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > Insulin Resistant dyslipidemic hamster model

insulin resistant dyslipidemic hamster model

A nutritional hamster model combining insulin resistance / diabetes and dyslipidemia

key benefits

  • Provides a noteworthy competitive advantage for your compound effects on both insulin resistance/diabetes, dyslipidemia and hepatic steatosis.
  • To select the best drug candidate in a very reproducible model with lipoprotein metabolism similar to humans.
  • To test the efficacy of novel drugs affecting both glucose and lipoprotein metabolism in a model validated with reference compounds.

pharmacological validation

  • Positive reference compounds: fenofibrate, rosiglitazone, sitagliptin

Fact sheet

Insulin resistant and dyslipidemic hamster model

REFERENCES

Briand F. et al. EASD, September 14-18, 2015, Stockholm, Sweden.
ico-link
Briand F. et al. Eur J Pharmacol. 2014 October;740: 135–143.
ico-link
Briand F. et al, Atherosclerosis. 2014, 233(2): 359-362.
ico-link
Briand F. et al. J Nutr. 2012 Apr;142(4):704-9.